

Insights into the Possible Mechanisms By Which Platelet-Activating Factor and PAF-receptors Function in Vascular Smooth Muscle in Magnesium Deficiency and Vascular Remodeling: Possible Links to Atherogenesis, Hypertension and Cardiac Failure

Editorial

Altura BM^{1,2,3,4,5*}, Shah NC^{1,5}, Gatha J. Shah¹, Pérez-Abela JL⁶, Altura BT^{1,3,4,5}¹Department of Physiology & Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY, USA.²Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA.³Center for Cardiovascular and Muscle Research, SUNY Downstate Medical Center, Brooklyn, NY, USA.⁴The School of Graduate Studies in Molecular and Cellular Science, State University of New York Downstate Medical Center, Brooklyn, NY, USA.⁵Bio-Defense Systems, Inc, Rockville Centre, NY, USA.⁶Instituto Bien de Salud, Lima, Peru.

Keywords: PAF; Sphingolipids; Atherosclerosis; Hypertension; Cardiac Failure; Ceramide.

Introduction

Platelet-activating factor (PAF) is a phospholipid mediator and cell signaling molecule which displays multiple biological and pathophysiological attributes, running the gamut from inflammation to cell differentiation and proliferation [1-4]. As is well-known, PAF interacts with specific membrane PAF-receptors (PAF-Rs) to initiate all cellular responses via specific G-protein-coupled receptors [1-4]. Although these initiated membrane receptor phenomena are mostly established for several tissue-cell systems [1-8], exactly how PAF and PAF-Rs cause vascular remodeling in hypertension and atherosclerosis is not clear. A little more than 15 years ago, PAF was identified as a molecule that stimulated activation of nuclear factor-kappaB (NF-kB) [1, 2, 8].

NF-kB, magnesium deficiency, PAF and sphingolipids

NF-kB is now known to be a prime regulator of growth processes, differentiation, cell migration, and cell death [for reviews, see [9-12], all factors required for vascular remodeling in hypertension and atherosclerosis [13, 14]. NF-kB is clearly a major transcription factor and a pleiotrophic regulator of numerous genes involved in inflammatory processes and epigenetic phenomena [9-12, 15]. NF-kB is now thought to be a pivotal molecule in atherosclerosis, hypertension, cardiac failure and stroke [14-19]. As of now,

it is still not clear as to what factor(s) initiates expression of these molecular events. We were the first laboratory to suggest and provide evidence for a role for activation of NF-kB in the cardiovascular manifestations, particularly atherosclerosis, noted in magnesium deficiency (MgD) [20-22]. We demonstrated that when vascular smooth muscle (VSM) cells were exposed to low concentrations of extracellular, ionized Mg ($[Mg^{2+}]_o$), a concentration-dependent upregulation of NF-kB took place; the lower the $[Mg^{2+}]_o$, the faster and greater the upregulation of NF-kB [20-22]. A similar situation appears to have been reported for endothelial cells [23]. Recently, we have reported that lowering $[Mg^{2+}]_o$ also results in a synthesis and release of activated PAF [24] concomitant with an upregulation of five major sphingolipid enzymatic pathways responsible for formation of ceramide and sphingosine, prior to NF-kB upregulation [18, 20, 21, 24-31].

Magnesium deficiency and activation of sphingolipid pathways in cardiovascular tissues and cells

The *de novo* synthesis of sphingomyelin is brought about via the action of serine palmitoyl-CoA transferase (SPT), 3-ketosphinganine reductase, ceramide synthase (CS), dihydroceramide desaturase, and SM synthase (SMS; ref [32]). SMS requires phosphatidylcholine (PC) and ceramide as substrates to manufacture SM and diacylglycerol (DAG; see ref. [32]). This reaction directly affects SM, PC, and ceramide as well as DAG levels

*Corresponding Author:

Burton M. Altura,
Professor, Department of Physiology and Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA.
Tel: 718-270-2194
E-mail: baltura@downstate.edu

Received: February 18, 2016

Published: February 22, 2016

Citation: Altura BM et al., (2016) Insights into the Possible Mechanisms by Which Platelet-Activating Factor and PAF-receptors Function in Vascular Smooth Muscle in Magnesium Deficiency and Vascular Remodeling: Possible Links to Atherosclerosis, Hypertension and Cardiac Failure. *Int J Cardiol Res.* 3(1e), 1-3. doi: <http://dx.doi.org/10.19070/2470-4563-160001e>

Copyright: Altura BM® 2016. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

in cells. Two of us [21, 33] have previously noted, using primary cerebral, coronary, and peripheral VSM cells in culture, as well as intact ventricular and atrial myocardial muscle obtained from rats after 21 days of short-term MgD [25-37], that variation of $[Mg^{2+}]_0$ influences the cellular levels of SM, PC, DAG, sphingosine, and ceramide. Our *in vitro* and *in vivo* studies clearly demonstrated that low $[Mg^{2+}]_0$ resulted in cellular synthesis and release of ceramide due to upregulation of SPT 1 and SPT 2, CS, SMS synthase, and a "salvage pathway" [25-31]. Ceramide is now thought to play important roles in fundamental pathophysiologic processes such as cell proliferation, membrane-receptor functions, angiogenesis, atherogenesis, immune inflammatory responses, cell adhesion, programmed cell death (i.e., apoptosis), and senescence among other functions [18, 25-31, 33-39]. It should be recalled, here, that MgD environments, both *in vivo* and *in vitro*, have repeatedly been shown to produce arterial and arteriolar contraction, vasospasm and vascular remodeling [18, 20, 22, 40-51], which we have demonstrated to involve ceramide (and other sphingolipids), PAF, cellular entry and intracellular release of free Ca^{2+} , and activation of PKC isozymes, mitogen-activated protein kinases (MAPKs), MAPK kinases, tyrosine protein kinases, P-I-3 kinases, and PAF among other cellular signaling molecules [18, 24, 33, 40-51].

PAF, magnesium deficiency, ceramide, and activation of proto-oncogenes

The proto-oncogene families, particularly c-fos and c-jun, are two principal players in regulation of cell growth, differentiation, cell migration, and cell death; all important factors in vascular remodeling, as particularly observed in at herogenesis, hypertension, and cardiac failure [11, 13, 14]. It is, however, not clear how these proto-oncogenes are activated in vascular disease processes. Approximately 15 years ago, we discovered that low $[Mg^{2+}]_0$ resulted in upregulation of both c-fos and c-jun in several types of VSM cells; the lower the $[Mg^{2+}]_0$, the faster and the greater the magnitudes of the upregulation of these two proto-oncogenes [22]. In addition, we found that rats given diets reduced in Mg for 21 days resulted in upregulation of c-fos and c-jun in ventricular and atrial myocardial muscle cells [29]. Reduction in extracellular calcium levels resulted in inhibition of these events [22]. Very recently, we reported that exposure of several types of primary cultured VSM cells, from at least three different mammalian species, to low $[Mg^{2+}]_0$ promoted synthesis and release of PAF and ceramide prior to upregulation of the proto-oncogenes [24]. In very recent experiments, we found that use of several different, specific antagonists of PAF-Rs attenuated, greatly, the PAF-stimulated formation of the proto-oncogenes and ceramide in several types of primary cultured VSM cells, pointing to a novel, new pathway in MgD [[24]; unpublished findings].

Conclusions

We believe our new findings on PAF, proto-oncogenes, and sphingolipids, e.g, ceramide and sphingosine, probably point to fundamental roles for the upstream regulation of both proto-oncogenes and sphingolipids in both VSM and cardiac muscle cells. These new, exciting findings probably will also be helpful in explaining many of the known cardiovascular manifestations of MgD, particularly vascular remodeling seen in atherosclerosis and hypertension. Last, but not least, our new studies should be useful in future studies designed to counteract many of the

cardiovascular manifestations of MgD.

Acknowledgments

Some of the original studies mentioned in this report were supported, in part, by Research Grants from The National Heart, Lung and Blood Institute, The National Institute on Drug Abuse, The National Institute on Mental Health and The National Institute on Alcoholism and Alcohol Abuse awarded to B.M.A. and B.T. A.

References

- Chao W, Olson MS (1993) Platelet-activating factor: receptors and signal transduction. *Biochem J* 292(Pt 3): 617-629.
- Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM (2000) Platelet-activating factor and related lipid mediators. *Annu Rev Biochem* 69: 419-450.
- Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM (2002) The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. *Crit Care Med* 30(5 Suppl): S294-S301.
- Montrucchio G, Alloati G, Camussi G (2000) Role of platelet-activating factor in cardiovascular pathophysiology. *Physiol Rev* 80(4): 1669-1699.
- Claing A, Shbaklo H, Plante M, Bkaily G, D'Orleans-Juste P (2002) Comparison of the contractile and calcium-increasing properties of platelet-activating factor and endothelin in the rat mesenteric artery and vein. *Br J Pharmacol* 135(2): 433-443.
- Lang PA, Kempe DS, Tanneur V, Eisle K, Klarl BA, et al. (2005) Stimulation of erythrocyte ceramide formation by platelet-activating factor. *J Cell Sci* 118 (Pt 6): 1233-1243.
- Ying-fang S, Jing-fang H, Huan-zhang L, Hao-wen Q (2007) Effect of platelet-activating factor on cell proliferation & NF-kappaB activation in airway smooth muscle cells in rats. *Indian J Med Res* 126(2): 139-145.
- Predescu S, Knezevic I, Bardita C, Neamu RF, Brovcovych V, et al. (2013) Platelet-activating factor -induced ceramide micro-domains drive endothelial NOS activation and contribute to barrier dysfunction. *PLOS One* 8(9): e75846.
- Barnes JP, Karin M (1997) Nuclear factor-kappaB--A pivotal transcription factor in chronic inflammatory disease. *N Engl J Med* 336(15): 1066-1071.
- Baeuerle PA, Baltimore D (1996) NF-kappaB: ten years after. *Cell* 87(1): 13-20.
- Ransone LJ, Verma IM (1990) Nuclear proto-oncogenes fos and jun. *Annu Rev Cell Biol* 6: 539-557.
- Hayden MS, Ghosh S (2011) NF-kB in immunology. *Cell Res* 21(2): 223-244.
- Intengan HD, Schiffrin EL (2001) Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. *Hypertension* 38(3 Pt 2): 581-587.
- Kumar V, Abbas AK, Fasuto N, Aster JC (2010) Robbins and Cotran Pathologic Basis of Disease. (8th edtn), Saunders, Philadelphia.
- Bourcier T, Sukhova G, Libby P (1997) The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle *in vitro* and in human atherosclerosis. *J Biol Chem* 272(25): 15817-15824.
- Momaco C, Andreacos E, Kirkadidis S, Mauri C, Bicknell C, et al. (2004) Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. *Proc Natl Acad Sci USA* 101(15): 5634-5639.
- Altura BM, Altura BT (2007) Magnesium: forgotten mineral in cardiovascular biology and angiogenesis. In *New Perspectives in Magnesium Research*. Springer, London. 239-260.
- Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. *Nat Immunol* 12(3): 204-212.
- Altura BM, Altura BT (1995) Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. *Cell Mol Biol Res* 41(5): 347-359.
- Morrill GA, Gupta RK, Kostellow AB, Ma GY, Zhang A, et al. (1998) Mg^{2+} modulates membrane sphingolipids and lipid second messenger levels in vascular smooth muscle cells. *FEBS Lett* 440(1-2): 167-171.
- Altura BM, Kostellow AB, Zhang A, Li W, Morrill GA, et al. (2003) Expression of the nuclear factor-kappaB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg^{2+} in aortic and cerebral vascular smooth muscle cells: possible links to hypertension, atherogenesis, and stroke. *Am J Hypertens* 16(9 Pt 1): 701-707.

- [22]. Maier JA (2012) Endothelial cells and magnesium: implications in atherosclerosis. *Clin Sci* 122(9): 397-407.
- [23]. Altura BM, Li W, Zhang A, Zheng T, Shah NC, et al. (2016) Expression of PAF by low extracellular Mg^{2+} in aortic, cerebral and piglet coronary arterial vascular smooth muscle cells: cross-talk with ceramide production, DNA, nuclear factor-kB and proto-oncogenes: possible links to inflammation, atherogenesis, hypertension, sudden cardiac death in children and infants, stroke, and aging: hypothesis and review. *Int J Clin Exp Med*, in press.
- [24]. Altura BM, Shah NC, Li Z, Jiang XC, Perez-Albela JL, et al. (2010) Magnesium deficiency upregulates serine palmitoyl transferase (SPT 1 and SPT 2) in cardiovascular tissues: relationship to serum ionized Mg and cytochrome C. *Am J Physiol Heart Circ Physiol* 299(3): H932-H938.
- [25]. Altura BM, Shah NC, Li Z, Jiang XC, Zhang A, et al. (2010) Short-term magnesium deficiency upregulates sphingomyelin synthase and p53 in cardiovascular tissues and cells: relevance to the de novo synthesis of ceramide. *Am J Physiol Heart Circ Physiol* 299(6): H2046-H2055.
- [26]. Altura BM, Shah NC, Shah G, Zhang A, Li W, et al. (2012) Short-term magnesium deficiency upregulates ceramide synthase in cardiovascular tissues and cells: cross-talk among cytokines, Mg^{2+} , NF-kB, and de novo ceramide. *Am J Physiol Heart Circ Physiol* 302(1): H319-H332.
- [27]. Shah NC, Liu JP, Iqbal J, Hussain M, Jiang XC, et al. (2011) Mg deficiency results in modulation of serum lipids, glutathione, and NO synthase isozyme activation in cardiovascular tissues: relevance to de novo synthesis of ceramide, serum Mg^{2+} and atherogenesis. *Int J Clin Exp Med* 4(2): 103-118.
- [28]. Altura BM, Shah NC, Shah GJ, Li W, Zhang A, et al. (2013) Magnesium deficiency upregulates sphingomyelinases in cardiovascular tissues and cells: cross-talk among proto-oncogenes, Mg^{2+} , NF-kB and ceramide and their potential relationships to resistant hypertension, atherogenesis and cardiac failure. *Int J Clin Exp Med* 6(10): 861-879.
- [29]. Altura BM, Shah NC, Shah GJ, Zhang A, Li W, et al. (2014) Short-term magnesium deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells; relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-zeta: hypothesis and review. *Int J Clin Exp Med* 7(1): 1-21.
- [30]. Shah NC, Shah GJ, Li Z, Jiang XC, Altura BT, et al. (2014) Short-term magnesium deficiency downregulates telomerase, upregulates neutral sphingomyelinase and induces oxidative DNA damage in cardiovascular tissues: relevance to atherogenesis, cardiovascular diseases and aging. *Int J Clin Exp Med* 7(3): 497-514.
- [31]. Merrill AH Jr, Jones DD (1990) An update of the enzymology and regulation of sphingomyelin metabolism. *Biochim Biophys Acta* 1044(1): 1-12.
- [32]. Morrill GA, Gupta RK, Kostellow AB, Ma GY, Zhang A, et al. (1997) Mg^{2+} modulates membrane lipids in vascular smooth muscle: a link to atherogenesis. *FEBS Lett* 408(2): 191-194.
- [33]. Haimovitz-Friedman A, Kolesnick RN, Fuks Z (1997) Ceramide signaling in apoptosis. *Br Med Bull* 53(3): 539-553.
- [34]. Hannun YA, Obeid LM (2002) The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. *J Biol Chem* 277(29): 25847-25850.
- [35]. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T (2001) Ceramide in apoptosis signaling: relationship with oxidative stress. *Free Radic Biol Med* 31(6): 717-728.
- [36]. Augé N, Nègre-Salvayre A, Salvayre R, Levade T (2000) Sphingomyelin metabolites in vascular signaling and atherosclerosis. *Prog Lipid Res* 39(3): 207-239.
- [37]. Pandey S, Murphy RF, Agrawal DK (2007) Recent advances in the immunobiology of ceramide. *Exp Mol Pathol* 82(3): 298-309.
- [38]. Villani M, Subathra M, Im YR, Choi Y, Signorelli P, et al. (2008) Sphingomyelin synthases regulate production of diacylglycerol at the Golgi. *Biochem J* 414(1): 31-41.
- [39]. Altura BM, Altura BT (1974) Magnesium and contraction of arterial smooth muscle. *Microvasc Res* 7(2): 145-155.
- [40]. Altura BM, Altura BT (1978) Magnesium and vascular tone and reactivity. *Blood Vessels* 15: 5-16.
- [41]. Altura BT, Altura BM (1980) Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries. *Neurosci Lett* 20(3): 323-327.
- [42]. Turlapaty PD, Altura BM (1980) Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. *Science* 208(4440): 198-200.
- [43]. Altura BM, Altura BT (1981) Magnesium and contraction of vascular smooth muscles: relationship to some vascular diseases. *Fed Proc* 40(12): 2672-2679.
- [44]. Altura BM, Altura BT, Carella A, Turlapaty PD (1981) Hypomagnesemia and vasoconstriction: Possible relationship to etiology of sudden death ischemic heart disease and hypertensive vascular diseases. *Artery* 9(3): 212-231.
- [45]. Altura BM, Turlapaty PD (1982) Withdrawal of magnesium enhances coronary arterial spasms produced by vasoactive agents. *Br J Pharmacol* 77(4): 649-659.
- [46]. Altura BM, Altura BT, Carella A (1983) Magnesium deficiency-induced spasms of umbilical vessels: relation to preeclampsia, hypertension, growth retardation. *Science* 221(4608): 376-378.
- [47]. Altura BM, Altura BT, Gebrewold A, Ising H, Gunther T (1984) Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. *Science* 223(4642): 1315-1317.
- [48]. Yang ZW, Wang J, Altura BT, Altura BM (2000) Extracellular Magnesium deficiency induces contraction of arterial muscle: role of PI3 kinases and MAPK signaling pathways. *Pflug Arch* 439(3): 240-247.
- [49]. Yang ZW, Wang J, Zheng T, Altura BT, Altura BM (2000) Low extracellular Mg^{2+} induces contraction and $[Ca^{2+}]_i$ rises in cerebral arteries: roles of Ca^{2+} , PKC and PI-3 kinases. *Am J Physiol Heart Circ Physiol* 279: H2898-H2907.
- [50]. Yang ZW, Wang J, Zheng T, Altura BT, Altura BM (2000) Low extracellular Mg induces contraction of cerebral arteries: roles of tyrosine and mitogen-activated protein kinases. *Am J Physiol Heart Circ Physiol* 279(1): H185-H194.